Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery

Figures & data

Table 1. Clinical inputs.

Clinical outcomes	HEMOPATCH	SOC	p-value	Data source
Hemostasis success rate	97.6%	65.8%	<.001^a	Weltert et al.^19, Table II
Need for autologous blood transfusions within 4 days of surgery	23.5%	34.0%	.24
Need for surgical revision from intra-operative bleeding	4.7%	5.8%	.30

^a Significant difference between the groups (p < .05).

Table 2. Cost inputs—surgery-related costs.

Surgery-related input categories	Italy (€)	Spain (€)	France (€)	UK (£)	Sources
Product cost for average surgical case					HEMOPATCH ASP per unit in 4.5 × 9 cm pack, SOC lowest allowable assumption
Using HEMOPATCH	263.81	241.53	258.00	274.24
Using SOC	0.01	0.01	0.01	0.01
Cost of cardiac surgery, no complication	8,998	8,281	4,553	7,738	Italy^20–22 Spain^23–26 France^21^,^27^,^28 UK^29^,^30
Incremental cost of revision	2,086.49	5,581.55	1,943.00	1,521.00
Incremental hospital cost of a single unit allogenic blood product with plasma	222.20	157.09	143.00	121.85

Figure 1. Estimated cost impact of reduced revisions and transfusions using HEMOPATCH vs SOC in an average Italian hospital performing 574 cardiac surgical procedures per year.

Figure 2. One-way sensitivity analysis results for (a) an Italian, (b) a Spanish, (c) a French, and (d) a British Hospital Performing 574 Cardiac Surgeries per Year.

Table 1A. Probability distributions for clinical inputs

Parameter	Base estimate	Probability distribution
Average number of cardiac surgical procedures per year	574	Log normal
Hemostasis success rate - HEMOPATCH	0.98	Log normal
Hemostasis success rate - SOC	0.66	Log normal
Surgical revisions
Ratio for surgical revision due to intra-operative bleeding - HEMOPATCH	0.05	Log normal
Ratio for surgical revision due to intra-operative bleeding - SOC	0.06	Log normal
Blood product transfusions
Ratio for autologous blood transfusion - HEMOPATCH	0.24	Log normal
Ratio for autologous blood transfusion - SOC	0.34	Log normal

Table 2A. Probability distributions for cost inputs.

Parameter	Base estimate	Probability distribution
Italy
HEMOPATCH unit cost	263.81	Log normal
SOC unit cost	0.01	Log normal
Cost of cardiac surgery, without complication, without revision, without blood product transfusion	8,998.63	Normal
Incremental cost of revision	2,086.49	Gamma
Incremental hospital cost of a single unit of allogenic blood product with plasma	222.20	Log normal for incremental cost
Average number of blood products transfused per surgery	2	Log normal
Spain
HEMOPATCH unit cost	241.53	Log normal
SOC unit cost	0.01	Log normal
Cost of cardiac surgery, without complication, without revision, without blood product transfusion	8,281.22	Normal
Incremental cost of revision	5,581.55	Gamma
Incremental hospital cost of a single unit of allogenic blood product with plasma	157.09	Log normal for incremental cost
Average number of blood products transfused per surgery	2	Log normal
France
HEMOPATCH unit cost	258	Log normal
SOC unit cost	0.01	Log normal
Cost of cardiac surgery, without complication, without revision, without blood product transfusion	4,553	Normal
Incremental cost of revision	1,943	Gamma
Incremental hospital cost of a single unit of allogenic blood product with plasma	143	Log normal for incremental cost
Average number of blood products transfused per surgery	2	Log normal
UK
HEMOPATCH unit cost	274.24	Log normal
SOC unit cost	0.01	Log normal
Cost of cardiac surgery, without complication, without revision, without blood product transfusion	7,738	Normal
Incremental cost of revision	1,521	Gamma
Incremental hospital cost of a single unit of allogenic blood product with plasma	121.85	Log normal for incremental cost
Average number of blood products transfused per surgery	2	Log normal

Weltert L, D’Aleo S, Chirichilli I, et al. Prospective randomized clinical trial of HEMOPATCH topical sealant in cardiac surgery. Surg Technol Int 2016;29 [Epub ahead of print]

 PubMedGoogle Scholar

Natour E, Suedkamp M, Dapunt OE. Assessment of the effect on blood loss and transfusion requirements when adding a polyethylene glycol sealant to the anastomotic closure of aortic procedures: a case–control analysis of 102 patients undergoing Bentall procedures. J Cardiothoracic Surg 2012;7:105

 PubMed Web of Science ®Google Scholar

Agence Technique de l'Information sur l'Hospitilisation. Analyse de la base nationale hospitaliere. Lyon: PMSI; 2013. French

 Google Scholar

Ministère des Solidarités et de la Santé. Relatif au tarif de cession des produits sanguins labiles, vrsion consolidee du 29/12/14. Paris: Journal Officiel de la République Française; 2017. French

 Google Scholar

NHS National Tariff Payment System 2016/17 [Internet]. London: NHS England; 2016. Available at: https://www.gov.uk/government/publications/nhs-national-tariff-payment-system-201617

 Google Scholar

NICE. Costing statement: Blood transfusion implementing the NICE guideline on blood transfusion (NG24). London: NICE; 2015

 Google Scholar